Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
expanded allogeneic umbilical cord mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Expanded allogeneic umbilical cord mesenchymal stem cells (UC-MSCs) are an investigational cell therapy derived from the Wharton's jelly of the umbilical cord. These cells are isolated from healthy donors and expanded in vitro to reach therapeutic doses. UC-MSCs are characterized by their potent paracrine activity, secreting a variety of anti-inflammatory cytokines, pro-angiogenic factors, and trophic molecules that modulate the immune response and promote tissue repair. In the context of preterm infants with bronchopulmonary dysplasia (BPD), these cells are administered intravenously to mitigate lung inflammation and support the development of alveolar and vascular structures, potentially reducing the severity of chronic lung disease and associated neonatal comorbidities.
- Other names
- expanded allogeneic umbilical cord mesenchymal cellsUC-MSCsumbilical cord-derived mesenchymal stem cellsallogeneic UC-MSCsexpanded allogeneic fetal umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on expanded allogeneic umbilical cord mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on expanded allogeneic umbilical cord mesenchymal stem cells.